Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound will start IND enabling studies the second quarter 2019.
Recent News
- Asabys-backed Oriva Therapeutics launches to advance novel treatments for women’s health
- Medibiofarma Successfully Completes Phase 2A Clinical Trial of MBF-118 for Fibrotic Crohn’s Disease
- Medibiofarma Receives 2nd Funding Award from the Crohn’s & Colitis Foundation to Support Development of a New Antifibrotic Therapy
- Palobiofarma and Medibiofarma open new headquarters in the AINbuilding in Cordovilla, Spain
- Medibiofarma S.L. announced the award of the European CommissionSeal of Excellence for their clinical asset MBF-015.